TY - JOUR
T1 - Cerebrospinal fluid tau in dementia disorders
T2 - A large scale multicenter study by a Japanese study group
AU - Shoji, Mikio
AU - Matsubara, Etsuro
AU - Murakami, Tetsuro
AU - Manabe, Yasuhiro
AU - Abe, Koji
AU - Kanai, Mitsuyasu
AU - Ikeda, Masaki
AU - Tomidokoro, Yasushi
AU - Shizuka, Masami
AU - Watanabe, Mitsunori
AU - Amari, Masakuni
AU - Ishiguro, Koji
AU - Kawarabayashi, Takeshi
AU - Harigaya, Yasuo
AU - Okamoto, Koichi
AU - Nishimura, Tsuyosi
AU - Nakamura, Yu
AU - Takeda, Masatoshi
AU - Urakami, Katsuya
AU - Adachi, Yoshiki
AU - Nakashima, Kenji
AU - Arai, Hiroyuki
AU - Sasaki, Hidetada
AU - Kanemaru, Kazutomi
AU - Yamanouchi, Hiroshi
AU - Yoshida, Yasuji
AU - Ichise, Kunihiro
AU - Tanaka, Kuniaki
AU - Hamamoto, Makoto
AU - Yamamoto, Hideki
AU - Matsubayashi, Takeyuki
AU - Yoshida, Hiroshi
AU - Toji, Hiromasa
AU - Nakamura, Shigenobu
AU - Hirai, Shunsaku
N1 - Funding Information:
Supported by Grants-in Aid for the Primary Amyloidosis Research Committee (S Ikeda and T Ishihara), surveys and research on special disease from Ministry of Health, Labor and Welfare of Japan and by Grants-in Aid for Scientific Research (C) (12670592, 12670593) and Scientific research on Priority Areas (C) -Advanced Brain Science Project -from the Ministry of Education, Culture, Sports, Science and Technology, Japan. This study included 236 CSF samples from the GTT1 study by Kanai M et al. [20] .
PY - 2002
Y1 - 2002
N2 - A large scale multicenter study of cerebrospinal fluid (CSF) tau levels was conducted to determine the cut-off value, sensitivity and specificity for clinical usage as a biomarker of Alzheimer's disease (AD). Its use for early and differential diagnosis and the factors that increase CSF tau levels were also examined. CSF samples from a total of 1,031 subjects including 366 patients with AD, 168 patients with non-Alzheimer type dementia (NA), 316 patients with non-dementia neurological diseases (ND) and 181 normal controls (NC) were measured using ELISA for tau. The cut-off value of tau, 375 pg/ml, showed 59.1% sensitivity and 89.5% specificity for diagnosis of AD compared with the other groups. The tau levels were increased from the early to late stages of AD. Elevation of CSF tau in the non-tauopathy and tauopathy dementia groups, chronic and acute damage to the cerebrum, and meningeal disturbance were other factors that required attention for clinical practice. Measurement of CSF tau was useful as a biomarker for early and differential diagnosis of AD.
AB - A large scale multicenter study of cerebrospinal fluid (CSF) tau levels was conducted to determine the cut-off value, sensitivity and specificity for clinical usage as a biomarker of Alzheimer's disease (AD). Its use for early and differential diagnosis and the factors that increase CSF tau levels were also examined. CSF samples from a total of 1,031 subjects including 366 patients with AD, 168 patients with non-Alzheimer type dementia (NA), 316 patients with non-dementia neurological diseases (ND) and 181 normal controls (NC) were measured using ELISA for tau. The cut-off value of tau, 375 pg/ml, showed 59.1% sensitivity and 89.5% specificity for diagnosis of AD compared with the other groups. The tau levels were increased from the early to late stages of AD. Elevation of CSF tau in the non-tauopathy and tauopathy dementia groups, chronic and acute damage to the cerebrum, and meningeal disturbance were other factors that required attention for clinical practice. Measurement of CSF tau was useful as a biomarker for early and differential diagnosis of AD.
KW - Alzheimer's disease
KW - Cerebrospinal fluid
KW - Diagnosis
KW - Large scale multicenter study
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=0036230086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036230086&partnerID=8YFLogxK
U2 - 10.1016/S0197-4580(01)00309-8
DO - 10.1016/S0197-4580(01)00309-8
M3 - Article
C2 - 11959397
AN - SCOPUS:0036230086
SN - 0197-4580
VL - 23
SP - 363
EP - 370
JO - Neurobiology of Aging
JF - Neurobiology of Aging
IS - 3
ER -